Show simple item record

dc.contributor.authorLove, Thorvardur Jon*
dc.contributor.authorQureshi, Abrar A*
dc.contributor.authorKarlson, Elizabeth Wood*
dc.contributor.authorGelfand, Joel M*
dc.contributor.authorChoi, Hyon K*
dc.date.accessioned2011-04-26T13:39:22Z
dc.date.available2011-04-26T13:39:22Z
dc.date.issued2011-04
dc.date.submitted2011-04-26
dc.identifier.citationArch Dermatol, 2003-2006. 2011, 147(4):419-24en
dc.identifier.issn1538-3652
dc.identifier.pmid21173301
dc.identifier.doi10.1001/archdermatol.2010.370
dc.identifier.urihttp://hdl.handle.net/2336/128660
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractObjectives To estimate the prevalence of the metabolic syndrome among individuals with psoriasis and to examine the association between these 2 conditions in the general US population. DESIGN: Cross-sectional health survey of a nationally representative random sample of the noninstitutionalized civilian US population. SETTING: The National Health and Nutrition Examination Survey, 2003-2006. PARTICIPANTS: The study included 6549 participants aged 20 to 59 years. MAIN OUTCOME MEASURES: Prevalence of the metabolic syndrome defined by the revised National Cholesterol Education Program Adult Treatment Panel III definition and odds ratios for associations after adjustment for age, sex, race/ethnicity, smoking status, and C-reactive protein levels. RESULTS: The prevalence of the metabolic syndrome was 40% among psoriasis cases and 23% among controls. According to 2008 US census data, the projected number of patients with psoriasis aged 20 to 59 years with the metabolic syndrome was 2.7 million. The univariate and multivariate odds ratios for patients with psoriasis and the metabolic syndrome were 2.16 (95% confidence interval, 1.16 to 4.03) and 1.96 (1.01 to 3.77), respectively. The most common feature of the metabolic syndrome among patients with psoriasis was abdominal obesity, followed by hypertriglyceridemia and low levels of high-density lipoprotein cholesterol. CONCLUSIONS: The prevalence of the metabolic syndrome is high among individuals with psoriasis. Given the serious complications associated with the metabolic syndrome, this frequent comorbidity should be recognized and taken into account in the long-term treatment of individuals with psoriasis.
dc.language.isoenen
dc.relation.urlhttp://dx.doi.org/10.1001/archdermatol.2010.370en
dc.subject.meshPsoriasisen
dc.subject.meshMetabolic Diseasesen
dc.subject.meshPubMed in processen
dc.titlePrevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003-2006en
dc.typeArticleen
dc.contributor.departmentMMSc, Department of Medicine, Landspitali Haskolasjukrahus, 108 Reykjavik, Iceland. thorvardur@gmail.com.en
dc.identifier.journalArchives of dermatologyen
html.description.abstractObjectives To estimate the prevalence of the metabolic syndrome among individuals with psoriasis and to examine the association between these 2 conditions in the general US population. DESIGN: Cross-sectional health survey of a nationally representative random sample of the noninstitutionalized civilian US population. SETTING: The National Health and Nutrition Examination Survey, 2003-2006. PARTICIPANTS: The study included 6549 participants aged 20 to 59 years. MAIN OUTCOME MEASURES: Prevalence of the metabolic syndrome defined by the revised National Cholesterol Education Program Adult Treatment Panel III definition and odds ratios for associations after adjustment for age, sex, race/ethnicity, smoking status, and C-reactive protein levels. RESULTS: The prevalence of the metabolic syndrome was 40% among psoriasis cases and 23% among controls. According to 2008 US census data, the projected number of patients with psoriasis aged 20 to 59 years with the metabolic syndrome was 2.7 million. The univariate and multivariate odds ratios for patients with psoriasis and the metabolic syndrome were 2.16 (95% confidence interval, 1.16 to 4.03) and 1.96 (1.01 to 3.77), respectively. The most common feature of the metabolic syndrome among patients with psoriasis was abdominal obesity, followed by hypertriglyceridemia and low levels of high-density lipoprotein cholesterol. CONCLUSIONS: The prevalence of the metabolic syndrome is high among individuals with psoriasis. Given the serious complications associated with the metabolic syndrome, this frequent comorbidity should be recognized and taken into account in the long-term treatment of individuals with psoriasis.


This item appears in the following Collection(s)

Show simple item record